Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5363 |
Name | myxoid liposarcoma |
Definition | A liposarcoma that is characterized by the presence of a hypocellular spindle cell proliferation set in a myxoid background and has_material_basis_in chromosomal translocations. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma myxoid liposarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 amp | Dovitinib | myxoid liposarcoma | sensitive | detail... |
FGFR2 amp | Dovitinib + Trabectedin | myxoid liposarcoma | sensitive | detail... |
FGFR2 amp | PD173074 | myxoid liposarcoma | sensitive | detail... |
FGFR2 amp | Infigratinib | myxoid liposarcoma | sensitive | detail... |
FGFR2 amp | PD173074 + Trabectedin | myxoid liposarcoma | sensitive | detail... |
FGFR2 amp | Infigratinib + Trabectedin | myxoid liposarcoma | sensitive | detail... |
PIK3CA H1047R | Copanlisib | myxoid liposarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02609984 | Phase II | Atezolizumab G305 + ID-LV305 | Trial of CMB305 and Atezolizumab in Patients With Sarcoma | Terminated | USA | 0 |
NCT02992743 | Phase II | Letetresgene autoleucel | Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma | Completed | USA | 0 |
NCT03450122 | Phase I | Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305 Aldesleukin + Cyclophosphamide Aldesleukin + Cyclophosphamide + ID-LV305 | Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma | Completed | USA | 0 |
NCT03670069 | Phase I | Itacitinib | Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas | Terminated | USA | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04044768 | Phase II | afamitresgene autoleucel | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT04526509 | Phase I | Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | Terminated | USA | SWE | NLD | DEU | CAN | AUS | 0 |
NCT04794127 | Phase II | Pioglitazone + Trabectedin | Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (TRABEPIO) | Recruiting | ITA | 0 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Terminated | USA | 0 |
NCT05043649 | Phase I | Camsirubicin + Pegfilgrastim | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Terminated | USA | 0 |
NCT05120271 | Phase Ib/II | BOXR1030 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) | Recruiting | USA | 0 |
NCT05597917 | Phase III | Trabectedin Trabectedin + tTF-NGR | tTF-NGR Randomized Study - STS (TRABTRAP) | Recruiting | DEU | AUT | 0 |
NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Recruiting | ESP | 0 |
NCT06083883 | Phase I | Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | Recruiting | USA | 0 |
NCT06217536 | Phase Ib/II | Lurbinectedin | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Not yet recruiting | 0 |